- Glenn Hearson
INCOGNITO Trial; Investigating COPD Lung Infections with two different inhalers
Updated: Sep 5, 2022
INCOGNITO is research project which is a partnership between Dr Dominick Shaw at Nottingham City Hospital and Dr James Chalmers at the University of Dundee, Scotland.
We believe the study is important for finding the best treatments for patients with COPD.
What is the purpose of this trial? Patients with Chronic Obstructive Pulmonary Disease (COPD) are frequently prescribed inhalers which contain steroids or bronchodilators to help reduce symptoms.
COPD patients are all different and there are now a number of different medications available. Some treatments that are of benefit to one group of patients may produce side effects in other patients.
This trial will compare two different inhalers that are both licensed for treatment of COPD. We believe that the two inhalers will have different effects on the bacteria that live in the lungs and on the inflammation in the lungs.
If we are right, it means that in future we could match the right inhaler to the right patient by measuring their levels of inflammation at the start, thereby reducing the risks of side effects and increasing the effectiveness of the treatment.
This study is fully completed